Investigating how a virus affects cancer cell behavior and treatment options
Official title: PARP1-Chromatin and NAD-Metabolism in EBV Epithelial Cancers
Funded at Wistar Institute · NIH-11085163 · Data updated 2026-11-12
This study is looking at how the Epstein-Barr Virus affects certain types of cancer and how a protein called PARP1 might help us find better treatments for patients with these cancers.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 11, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $475,815 |
| NIH project number | 5P01CA269043-03 |
| Project ID | NIH-11085163 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with EBV-positive epithelial cancers, such as gastric cancer.
✕Less likely to help
Patients with EBV-negative cancers or those without epithelial cancers may not benefit from this research.
What this research studies
This research focuses on understanding how Epstein-Barr Virus (EBV) influences the development and treatment of certain epithelial cancers. The team is exploring the role of a protein called PARP1 in regulating the virus's activity and its impact on cancer cell metabolism. By studying how PARP1 interacts with the EBV genome and affects gene expression, the researchers aim to identify new therapeutic strategies that could specifically target EBV-related tumors. This could lead to more effective treatments tailored for patients with these cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for patients with EBV-related epithelial cancers.
How similar studies have gone: Previous research has shown promising results in targeting PARP proteins in cancer treatment, indicating potential success for this approach.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Tempera, Italo — Wistar Institute
- Study coordinator: Tempera, Italo
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.